In a report released yesterday, from Guoyuan Securities (HK) maintained a Buy rating on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H, with a price target of HK$6.28. The company’s shares closed yesterday at HK$3.46.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Currently, the analyst consensus on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is a Moderate Buy with an average price target of HK$6.28.
Based on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$114.33 million and a GAAP net loss of HK$64.89 million. In comparison, last year the company earned a revenue of HK$78.82 million and had a GAAP net loss of HK$150.1 million
